Showing 5,981 - 6,000 results of 6,434 for search '"Medicine"', query time: 0.07s Refine Results
  1. 5981
  2. 5982
  3. 5983
  4. 5984
  5. 5985
  6. 5986
  7. 5987
  8. 5988
  9. 5989
  10. 5990

    Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement) by M. V. Maevskaya, M. Yu. Nadinskaia, E. N. Bessonova, N. I. Geyvandova, M. S. Zharkova, E. A. Kitsenko, N. V. Korochanskaya, I. A. Kurkina, A. L. Melikyan, V. G. Morozov, Yu. V. Khoronko, T. A. Deeva, K. A. Gulyaeva, V. T. Ivashkin

    Published 2024-08-01
    “…The Russian Scientific Liver Society selected a panel of experts in the field of therapeutic and surgical hepatology, hematology, transfusion medicine to make reasoned statements and recommendations on the issue of treatment of thrombocytopenia before elective surgery / invasive procedures in patients with liver cirrhosis.Results. …”
    Get full text
    Article
  11. 5991
  12. 5992

    Clinical Features and Prognosis of Double-Positive Anti-MDA5 and Anti-CCP Antibodies in Dermatomyositis: A Retrospective Study by Xu X, Zhu L, Li S, Wang G, Ge Y

    Published 2025-02-01
    “…Xiayu Xu,1 Longyang Zhu,2 Sizhao Li,3 Guochun Wang,3 Yongpeng Ge3 1Department of Rheumatology and Immunology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, People’s Republic of China; 2Peking University, China-Japan Friendship School of Clinical Medicine, Beijing, People’s Republic of China; 3Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, People’s Republic of ChinaCorrespondence: Yongpeng Ge, Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China, Email gyp2016@163.comObjective: To investigate the clinical features and prognosis of anti-melanoma differentiation-related gene 5 (MDA5) antibody and anti-cyclic citrullinated peptide (CCP) antibody double-positive dermatomyositis (DM) (MDA5+/CCP+ DM).Methods: A retrospective analysis of 264 consecutive cases of MDA5+ DM hospitalized from March 2018 to March 2022, and patients with anti-CCP antibodies were screened out. …”
    Get full text
    Article
  13. 5993

    Impacts of National Reimbursement Drug Price Negotiation on drug accessibility, utilization, and cost in China: a systematic review by Zheng Zhu, Jiawei Zhang, Zhihu Xu, Quan Wang, Yu Qi, Li Yang

    Published 2025-02-01
    “…Conclusion Evidence to date generally suggests the NRDPN policy is an effective way to decrease drug prices, improve access to innovative medicines, and improve fairness. It provides useful experience and lessons in improving access to innovative medicines for other low-and middle-income countries.…”
    Get full text
    Article
  14. 5994
  15. 5995
  16. 5996
  17. 5997
  18. 5998
  19. 5999
  20. 6000